What strategies help biotech startups navigate competing CRISPR patents?
Biotech startups navigate competing CRISPR patents using several key strategies, beginning with comprehensive freedom to operate (FTO) analyses to map the patent landscape [1][2]. Because foundational CRISPR-Cas9 IP involves overlapping claims and patent thickets [3], companies secure cross-licensing deals, sublicensing agreements, or institutional partnerships to obtain legal access [4][5]. Alternatively, startups pivot to alternative nucleases—such as engineered Cas12 variants or non-CRISPR systems—that fall outside foundational patent claims and offer simplified, lower-cost licensing [6][7][8]. While patent litigation creates uncertainty and substantial legal costs [9][10], investors often focus primarily on clinical efficacy and potential market uptake rather than IP disputes alone, provided the therapeutic value is high [11].
Would you also like to know how patent pools are used in the CRISPR sector?
Get more accurate answers with Super Pandi, upload files, personalized discovery feed, save searches and contribute to the PandiPedia.
Let's look at alternatives:
- Modify the query.
- Start a new thread.
- Remove sources (if manually added).
